ArticlePloS one2017
Tissue factor-dependent coagulation activation by heme: A thromboelastometry study.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 22 citations in OpenAlex.
- Sustained expression of hemopexin in an animal model of sickle cell anemia.Blood vessels, thrombosis & hemostasis · 2026Article
- Constitutive hypercoagulability in pediatric sickle cell disease patients with hemoglobin SS genotype.Research and practice in thrombosis and haemostasis · 2024Article
- Safety and feasibility of the gene transfer of hemopexin for conditions with increased free heme.Experimental biology and medicine (Maywood, N.J.) · 2023Article
- Evaluation of the mechanisms of heme-induced tissue factor activation: Contribution of innate immune pathways.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- SARS-CoV-2 Proteins Bind to Hemoglobin and Its Metabolites.International journal of molecular sciences · 2021Article
- Linking Labile Heme with Thrombosis.Journal of clinical medicine · 2021Review
- Thromboinflammatory mechanisms in sickle cell disease - challenging the hemostatic balance.Haematologica · 2020Article
- Pro-inflammatory Actions of Heme and Other Hemoglobin-Derived DAMPs.Frontiers in immunology · 2020Review
- Endothelial Barrier Integrity Is DisruptedFrontiers in immunology · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heme has been characterized as potent trigger of inflammation. In hemostasis, although heme has been shown to both induce and inhibit different compartments of hemostasis, its net effect on the hemostatic balance, and the biological relevance of these effects remain to be determined. Herein we evaluated the effect of heme on hemostasis using a global assay able to generate clinically relevant data in several other complex hemostatic diseases. Citrated whole blood samples from healthy participants were stimulated by heme or vehicle and incubated for 4h at 37°C. Rotational thromboelastometry was immediately performed. The participation of tissue factor in coagulation activation was evaluated using inhibitory antibody. Heme was able of inducing ex vivo coagulation activation in whole blood, affecting predominantly parameters associated with the initial phases of clot formation. This activation effect was at least partially dependent on hematopoietic tissue factor, since the effects of heme were partially abrogated by the inhibition of human tissue factor. In conclusion, using a global hemostasis assay, our study confirmed that heme is able to activate coagulation in whole blood, in a tissue factor-dependent way. These findings could explain the disturbance in hemostatic balance observed in conditions associated with the release of heme such as sickle cell disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.